Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
IMMX Stock Forecast 2026-2027
$4.96
Current Price
$239.36M
Market Cap
Buy 1
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to IMMX Price Targets
+141.9%
To High Target of $12.00
+93.5%
To Median Target of $9.60
+45.2%
To Low Target of $7.20
IMMX Price Momentum
-2.6%
1 Week Change
-20.0%
1 Month Change
+145.5%
1 Year Change
-5.2%
Year-to-Date Change
-35.8%
From 52W High of $7.73
+270.1%
From 52W Low of $1.34
📊 TOP ANALYST CALLS
Did IMMX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Immix Biopharma is one of their latest high-conviction picks.
Latest IMMX Stock Price Targets & Analyst Predictions
Based on our analysis of 2 Wall Street analysts, IMMX has a bullish consensus with a median price target of $9.60 (ranging from $7.20 to $12.00). The overall analyst rating is Strong Buy (10.0/10). Currently trading at $4.96, the median forecast implies a 93.5% upside. This outlook is supported by 1 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Robert Burns at HC Wainwright & Co., projecting a 141.9% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
IMMX Analyst Ratings
1
Buy
0
Hold
0
Sell
IMMX Price Target Range
Low
$7.20
Average
$9.60
High
$12.00
Current: $4.96
Latest IMMX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for IMMX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Dec 9, 2025 | HC Wainwright & Co. | Robert Burns | Buy | Maintains | $12.00 |
| Sep 12, 2025 | HC Wainwright & Co. | Robert Burns | Buy | Maintains | $8.00 |
| Jun 4, 2025 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $7.00 |
| Feb 10, 2025 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $7.00 |
| Jan 6, 2025 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $7.00 |
| Oct 3, 2024 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $7.00 |
| Aug 19, 2024 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $7.00 |
| Jul 26, 2024 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $7.00 |
| Jul 9, 2024 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $7.00 |
| Jul 1, 2024 | HC Wainwright & Co. | Robert Burns | Buy | Initiates | $7.00 |
| Aug 14, 2023 | Roth MKM | Jonathan Aschoff | Buy | Reiterates | $14.00 |
| Feb 22, 2023 | Roth MKM | Jonathan Aschoff | Buy | Initiates | $14.00 |
Immix Biopharma Inc. (IMMX) Competitors
The following stocks are similar to Immix Biopharma based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
IMMX
Immix Biopharma
mkt cap
256.63M
Immix Biopharma Inc. (IMMX) Financial Data
Immix Biopharma Inc. has a market capitalization of $239.36M with a P/E ratio of -6.5x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -182.5%.
Valuation Metrics
Market Cap
$239.36M
Enterprise Value
$134.24M
P/E Ratio
-6.5x
PEG Ratio
-9.6x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+9.6%
Current Ratio
1.5x
Debt/Equity
13.4x
ROE
-182.5%
ROA
-66.5%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Immix Biopharma Inc. (IMMX) Business Model
About Immix Biopharma Inc.
What They Do
Develops innovative therapies for oncology and immunotherapy.
Business Model
The company generates revenue through its proprietary SMARxT Platform, which enhances the therapeutic index of drugs for hematologic and solid tumors. Immix Biopharma is actively involved in various stages of drug development, including pre-clinical and clinical trials, aiming to ensure the efficacy and safety of its treatments.
Additional Information
Immix Biopharma is positioned as a key player in the biotech sector, contributing to advancements in cancer treatment protocols and potentially transforming patient management of life-threatening diseases. Its focus on innovation and patient-centered solutions makes it an attractive option for investors in the biotechnology field.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
18
CEO
Dr. Ilya Rachman M.B.A., M.D., Ph.D.
Country
United States
IPO Year
2021
Website
www.immixbio.comImmix Biopharma Inc. (IMMX) Latest News & Analysis
Latest News
Quick Summary
Immix Biopharma closed its underwritten offering of 19.1 million shares at $5.10 each, raising approximately $93.7 million in net proceeds.
Why It Matters
Immix Biopharma raised approximately $93.7 million through a stock offering, enhancing its financial position to fund operations and accelerate growth, which may boost investor confidence and stock value.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Immix Biopharma (IMMX) is progressing NXC-201 for AL amyloidosis, with high response rates. A $100 million financing enhances its position for a mid-2026 BLA submission, with peak revenues projected up to $1 billion.
Why It Matters
Immix Biopharma's promising CAR T therapy and strong financing enhance its growth potential, positioning it favorably for future revenue increases and valuation upside.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
NXC-201 achieved a complete response rate of 75% (15 out of 20) according to an independent review committee.
Why It Matters
A 75% complete response rate for NXC-201 indicates strong efficacy, potentially boosting investor confidence and driving stock value in related biotech firms.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Immix Biopharma, Inc. has priced an offering of 19.1 million shares at $5.10 each and pre-funded warrants at $5.09, aiming to raise $100 million. The offering closes around December 9, 2025.
Why It Matters
ImmixBio's $100 million capital raise at $5.10 per share indicates robust investor interest, potentially funding growth and development, which could impact future stock performance positively.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Michael Grabow, former Senior Commercial Leader at Chimerix, led the Go-To-Market Strategy for the rare disease therapeutic MODEYSO®, following Chimerix's acquisition by Jazz for $935 million.
Why It Matters
The acquisition of Chimerix by Jazz and the leadership of Grabow in launching MODEYSO® signals potential growth in rare disease markets, impacting future revenue and stock performance for Jazz.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Immix Biopharma: I Am Surprised To Reaffirm A 'Buy'
2 months ago
Quick Summary
Immix Biopharma's CAR T-cell therapy for AL amyloidosis shows early promise, with data presentation at ASH expected. The company has secured funding but faces cash concerns ahead of a potential FDA submission in 2026.
Why It Matters
Early signals for Immix Biopharma's CAR T-cell therapy could influence its FDA submission timeline. Funding secured alleviates immediate cash concerns, impacting investor confidence and stock performance.
Source: Seeking Alpha
Market Sentiment:
Positive
Frequently Asked Questions About IMMX Stock
What is Immix Biopharma Inc.'s (IMMX) stock forecast for 2026?
Based on our analysis of 2 Wall Street analysts, Immix Biopharma Inc. (IMMX) has a median price target of $9.60. The highest price target is $12.00 and the lowest is $7.20.
Is IMMX stock a good investment in 2026?
According to current analyst ratings, IMMX has 1 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $4.96. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for IMMX stock?
Wall Street analysts predict IMMX stock could reach $9.60 in the next 12 months. This represents a 93.5% increase from the current price of $4.96. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Immix Biopharma Inc.'s business model?
The company generates revenue through its proprietary SMARxT Platform, which enhances the therapeutic index of drugs for hematologic and solid tumors. Immix Biopharma is actively involved in various stages of drug development, including pre-clinical and clinical trials, aiming to ensure the efficacy and safety of its treatments.
What is the highest forecasted price for IMMX Immix Biopharma Inc.?
The highest price target for IMMX is $12.00 from Robert Burns at HC Wainwright & Co., which represents a 141.9% increase from the current price of $4.96.
What is the lowest forecasted price for IMMX Immix Biopharma Inc.?
The lowest price target for IMMX is $7.20 from at , which represents a 45.2% increase from the current price of $4.96.
What is the overall IMMX consensus from analysts for Immix Biopharma Inc.?
The overall analyst consensus for IMMX is bullish. Out of 2 Wall Street analysts, 1 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $9.60.
How accurate are IMMX stock price projections?
Stock price projections, including those for Immix Biopharma Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: January 15, 2026 3:14 AM UTC